Ardelyx Inc.

Mar 14, 2018

Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors

Feb 12, 2018

Ardelyx Announces Departure of Chief Scientific Officer

Jan 11, 2018

Stock Review for Biotech's Investors -- Ardelyx, Verastem, and Acceleron Pharma

Jan 03, 2018

Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference

Jan 03, 2018

Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C

Dec 11, 2017

Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China

Nov 28, 2017

Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan

Nov 21, 2017

Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline

Nov 07, 2017

Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress

Oct 16, 2017

Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling

Oct 11, 2017

Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

Aug 09, 2017

Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results

Aug 02, 2017

Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference